Showing 1 - 4 results of 4 for search 'Sylvain Laverdure', query time: 0.02s Refine Results
  1. 1
    Interleukin-27-induced HIV-resistant dendritic cells suppress reveres transcription following virus entry in an SPTBN1, autophagy, and YB-1 independent manner.

    Interleukin-27-induced HIV-resistant dendritic cells suppress reveres transcription following virus entry in an SPTBN1, autophagy, and YB-1 independent manner. by Tomozumi Imamichi, Qian Chen, Bharatwaj Sowrirajan, Jun Yang, Sylvain Laverdure, Mayra Marquez, Anthony R Mele, Catherine Watkins, Joseph W Adelsberger, Jeanette Higgins, Hongyan Sui

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    HIVGenoPipe: a nextflow pipeline for the detection of HIV-1 drug resistance using a real-time sample-specific reference sequence

    HIVGenoPipe: a nextflow pipeline for the detection of HIV-1 drug resistance using a real-time sample-specific reference sequence by Thoai Dotrang, Brad T. Sherman, Lisheng Dai, Muhammad Ayub Khan, Helene C. Highbarger, Whitney Bruchey, Sylvain Laverdure, Michael W. Baseler, Tomozumi Imamichi, Robin L. Dewar, Weizhong Chang

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment

    Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment by Elizabeth S. Munroe, Greg A. Grandits, Robert C. Hyzy, Hallie C. Prescott, Thomas W. Barrett, Robin L. Dewar, Nicole Engen, Anna L. Goodman, Timothy J. Hatlen, Helene Highbarger, Thomas L. Holland, Gareth Hughes, Tomas O. Jensen, Muhammad A. Khan, Ioannis Kalomenidis, Nayon Kang, Sylvain Laverdure, Prasad Manian, Vidya Menon, Ravi Patel, Srikanth Ramachandruni, Tauseef Rehman, Kathryn Shaw-Saliba, Birgit Thorup Røge, David M. Vock, Amy C. Weintrob, Barnaby E. Young, Anne P. Frosch, for the STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment.

    Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. by Elizabeth S Munroe, Greg A Grandits, Robert C Hyzy, Hallie C Prescott, Thomas W Barrett, Robin L Dewar, Nicole Engen, Anna L Goodman, Timothy J Hatlen, Helene Highbarger, Thomas L Holland, Gareth Hughes, Tomas O Jensen, Muhammad A Khan, Ioannis Kalomenidis, Nayon Kang, Sylvain Laverdure, Prasad Manian, Vidya Menon, Ravi Patel, Srikanth Ramachandruni, Tauseef Rehman, Kathryn Shaw-Saliba, Birgit Thorup Røge, David M Vock, Amy C Weintrob, Barnaby E Young, Anne P Frosch, STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: